Connection

AZIZ SHAIBANI to Male

This is a "connection" page, showing publications AZIZ SHAIBANI has written about Male.
Connection Strength

0.145
  1. Refractory Chronic Immune-mediated Demyelinating Polyneuropathy. Neurol Clin. 2020 08; 38(3):591-605.
    View in: PubMed
    Score: 0.022
  2. Swallowing-induced Supraventricular Tachyarrhythmia. Rev Cardiovasc Med. 2017; 18(1):53-58.
    View in: PubMed
    Score: 0.017
  3. Distal Myopathies: Case Studies. Neurol Clin. 2016 Aug; 34(3):547-64.
    View in: PubMed
    Score: 0.017
  4. Autosomal recessive posterior column ataxia with retinitis pigmentosa caused by novel mutations in the FLVCR1 gene. Int J Neurosci. 2015 Jan; 125(1):43-9.
    View in: PubMed
    Score: 0.014
  5. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med. 2012 Feb; 13(2):243-54.
    View in: PubMed
    Score: 0.012
  6. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009 Aug; 10(8):818-28.
    View in: PubMed
    Score: 0.010
  7. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
    View in: PubMed
    Score: 0.007
  8. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
    View in: PubMed
    Score: 0.006
  9. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021 05; 14(3):1176-1184.
    View in: PubMed
    Score: 0.006
  10. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020 08 11; 95(6):e755-e766.
    View in: PubMed
    Score: 0.005
  11. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019 09; 18(9):834-844.
    View in: PubMed
    Score: 0.005
  12. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI. Neurology. 2018 06 05; 90(23):e2034-e2041.
    View in: PubMed
    Score: 0.005
  13. Moving toes and myoclonus associated with hereditary neuropathy with liability to pressure palsy (HNPP). Muscle Nerve. 1997 Jul; 20(7):881-3.
    View in: PubMed
    Score: 0.004
  14. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 08 11; 375(6):511-22.
    View in: PubMed
    Score: 0.004
  15. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst. 2015 Dec; 20(4):363-71.
    View in: PubMed
    Score: 0.004
  16. Clinical and biochemical improvement of very long-chain acyl-CoA dehydrogenase deficiency in pregnancy. J Perinatol. 2010 Aug; 30(8):558-62.
    View in: PubMed
    Score: 0.003
  17. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007 Feb; 23(2):150-8.
    View in: PubMed
    Score: 0.002
  18. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand. 2006 Jun; 113(6):395-404.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.